Allergy Therapeutics plc Appointment of Mary Tavener as Non-Executive Director

Commenting on the appointment, Peter Jensen, Chairman of Allergy Therapeutics, said: “I am delighted to announce Mary’s appointment and welcome her to the Board. Mary has an excellent track record and an impressive breadth of executive experience, and we look forward to the invaluable and trusted perspective she will bring to the Board.”

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced that Mary Tavener will join the Board of Allergy Therapeutics as a Non-Executive Director with immediate effect. Mary will also join the Audit Committee of the Board and will work closely with the current chair Stephen Smith in anticipation of her succeeding Stephen as chair of the committee after the Group publishes its final results for the year ended 30 June 2019 in September.

Mary has extensive experience in the healthcare sector, having spent more than 19 years as Chief Financial Officer and Board member of AIM listed Advanced Medical Solutions.  At AMS, Mary was responsible for strategy and risk management, finance, operations, regulatory, and legal. During her tenure through to the end of 2018, AMS delivered 15 consecutive years of growth, listed on AIM, and successfully conducted several transformational M&A deals. Mary is a Fellow of the Chartered Institute of Management Accountants and a Fellow of the Association of Corporate Treasurers.  Prior to joining AMS, Mary was the Group Financial Controller of BTP plc.

Commenting on her appointment, Mary Tavener said: “Allergy Therapeutics has an excellent growth story since its formation as a small spinout from SmithKline Beecham in 1999. The business today has a broad range of assets in clinical development, a global presence across 23 markets, over 500 employees, and has achieved a 10% CAGR over the last 19 years as well as significant commercial success. I look forward to working with the Board to further develop Allergy’s leading position in the allergen immunotherapy sector.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Allergy therapeutics plc

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million